BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 14614017)

  • 41. Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome.
    Kielhorn E; Provost E; Olsen D; D'Aquila TG; Smith BL; Camp RL; Rimm DL
    Int J Cancer; 2003 Feb; 103(5):652-6. PubMed ID: 12494474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome.
    Woenckhaus C; Maile S; Uffmann S; Bansemir M; Dittberner T; Poetsch M; Giebel J
    Histol Histopathol; 2005 Apr; 20(2):501-8. PubMed ID: 15736055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.
    Weiss J; Heine M; Körner B; Pilch H; Jung EG
    Br J Dermatol; 1995 Jul; 133(1):23-31. PubMed ID: 7669636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytoplasmic phosphorylated ERK1/2 expression in patients with melanoma is associated with tumor stage and metastasis.
    Tseng YS; Wu PR; Lu JW; Wang YF; Yeh KT; Lin SH
    Biotech Histochem; 2022 Feb; 97(2):118-125. PubMed ID: 33902381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma.
    Andersen K; Nesland JM; Holm R; Flørenes VA; Fodstad Ø; Maelandsmo GM
    Mod Pathol; 2004 Aug; 17(8):990-7. PubMed ID: 15133476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Classification of CEA-related positivity in primary and metastatic malignant melanoma.
    Sanders DS; Evans AT; Allen CA; Bryant FJ; Johnson GD; Hopkins J; Stocks SC; Marsden JR; Kerr MA
    J Pathol; 1994 Apr; 172(4):343-8. PubMed ID: 8207615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in the presentation of nodular and superficial spreading melanomas over 35 years.
    Warycha MA; Christos PJ; Mazumdar M; Darvishian F; Shapiro RL; Berman RS; Pavlick AC; Kopf AW; Polsky D; Osman I
    Cancer; 2008 Dec; 113(12):3341-8. PubMed ID: 18988292
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estradiol-induced mitogen-activated protein kinase (extracellular signal-regulated kinase 1 and 2) activity in the frog (Rana esculenta) testis.
    Chieffi P; Colucci-D'Amato GL; Staibano S; Franco R; Tramontano D
    J Endocrinol; 2000 Oct; 167(1):77-84. PubMed ID: 11018755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease.
    Kneisel L; Strebhardt K; Bernd A; Wolter M; Binder A; Kaufmann R
    J Cutan Pathol; 2002 Jul; 29(6):354-8. PubMed ID: 12135466
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Melanoma Development and Progression Are Associated with Rad6 Upregulation and β -Catenin Relocation to the Cell Membrane.
    Rosner K; Mehregan DR; Kirou E; Abrams J; Kim S; Campbell M; Frieder J; Lawrence K; Haynes B; Shekhar MP
    J Skin Cancer; 2014; 2014():439205. PubMed ID: 24891954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pattern of the mononuclear infiltrate as a prognostic parameter in flat superficial spreading melanomas.
    Bröcker EB; Kolde G; Steinhausen D; Peters A; Macher E
    J Cancer Res Clin Oncol; 1984; 107(1):48-52. PubMed ID: 6699074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of beta-catenin expression is associated with disease progression in malignant melanoma.
    Osborne JE
    Br J Dermatol; 2002 Jun; 146(6):1104. PubMed ID: 12072090
    [No Abstract]   [Full Text] [Related]  

  • 53. Inflammatory IL-1β-driven JNK activation in stage III melanoma.
    Qin Y; Milton DR; Oba J; Ding Z; Lizée G; Ekmekcioglu S; Grimm EA
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):236-9. PubMed ID: 25546243
    [No Abstract]   [Full Text] [Related]  

  • 54. An observational study regarding the rate of growth in vertical and radial growth phase superficial spreading melanomas.
    Betti R; Agape E; Vergani R; Moneghini L; Cerri A
    Oncol Lett; 2016 Sep; 12(3):2099-2102. PubMed ID: 27602146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.
    Rinner B; Gandolfi G; Meditz K; Frisch MT; Wagner K; Ciarrocchi A; Torricelli F; Koivuniemi R; Niklander J; Liegl-Atzwanger B; Lohberger B; Heitzer E; Ghaffari-Tabrizi-Wizsy N; Zweytick D; Zalaudek I
    Sci Rep; 2017 May; 7(1):2098. PubMed ID: 28522871
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.
    Berzaghi R; Maia VS; Pereira FV; Melo FM; Guedes MS; Origassa CS; Scutti JB; Matsuo AL; Câmara NO; Rodrigues EG; Travassos LR
    Sci Rep; 2017 Jan; 7():40585. PubMed ID: 28079159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coexpression of SOX10/CD271 (p75(NTR)) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients.
    Barysch MJ; Levesque MP; Cheng P; Karpova MB; Mihic-Probst D; Civenni G; Shakhova O; Sommer L; Biedermann T; Schiestl C; Dummer R
    Dermatopathology (Basel); 2014; 1(1):35-46. PubMed ID: 27047921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
    Theocharis S; Kotta-Loizou I; Klijanienko J; Giaginis C; Alexandrou P; Dana E; Rodriguez J; Patsouris E; Sastre-Garau X
    Tumour Biol; 2014 Jul; 35(7):6455-65. PubMed ID: 24682903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.
    Lee MH; Huang Z; Kim DJ; Kim SH; Kim MO; Lee SY; Xie H; Park SJ; Kim JY; Kundu JK; Bode AM; Surh YJ; Dong Z
    Cancer Prev Res (Phila); 2013 May; 6(5):455-65. PubMed ID: 23447564
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.
    Levidou G; Saetta AA; Gigelou F; Karlou M; Papanastasiou P; Stamatelli A; Kavantzas N; Michalopoulos NV; Agrogiannis G; Patsouris E; Korkolopoulou P
    World J Surg Oncol; 2012 Feb; 10():47. PubMed ID: 22376079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.